YL202 is named as an intervention in 5 current clinical trials in our China and USA registers. 4 are recruiting patients now. The most common phase is Phase 3. The lead sponsor is MediLink Therapeutics (Suzhou) Co., Ltd. The most-studied condition is Non Small Cell Lung Cancer.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer
NCT07416994 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer
|
Phase 3 | Recruiting | MediLink Therapeutics (Suzhou) Co., Ltd. | China |
|
YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer
NCT07461454 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Breast Cancer
|
Phase 3 | Recruiting | MediLink Therapeutics (Suzhou) Co., Ltd. | China |
|
A Study of YL202 in Patients With Advanced Solid Tumors
NCT07202364 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Colorectal Cancer, Cervical Cancer
|
Phase 2 | Recruiting | MediLink Therapeutics (Suzhou) Co., Ltd. | China |
|
A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
NCT07169994 · ClinicalTrials.gov ↗ · Advanced Solid Tumors, Breast Cancer, Non Small Cell Lung Cancer
|
Phase 1/2 | Recruiting | MediLink Therapeutics (Suzhou) Co., Ltd. | China |
|
A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer
NCT05653752 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Breast Cancer
|
Phase 1 | Active, closed | MediLink Therapeutics (Suzhou) Co., Ltd. | USA, China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| MediLink Therapeutics (Suzhou) Co., Ltd. | 5 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 5 | 4 |
| Clinical trials in USA | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
5 current trials in our China and USA registers name YL202 as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 4 of the 5 trials are recruiting: 4 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is MediLink Therapeutics (Suzhou) Co., Ltd. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how YL202 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how YL202 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists YL202 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.